A medical breakthrough in the fight against pancreatic cancer is showing promising results after decades of research. The experimental drug, taken once a day, extends patients’ lives by slowing the progression of one of the deadliest cancers. Dr. Rachna Shroff, associate director of clinical investigations at the University of Arizona Comprehensive Cancer Center, joins Stephanie Sy for more.

Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.

The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung, colon and ovarian cancers.